EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A mouse mutant deficient in both neuronal ceroid lipofuscinosis‐associated proteins CLN3 and TPP1

David E Sleat iD, Whitney Banach-Petrosky, Katherine E Larrimore, Yuliya Nemtsova, Jennifer A Wiseman, Allison Najafi, Dymonn Johnson, Timothy A Poole, Keigo Takahashi, Jonathan D Cooper, Peter Lobel

Journal of Inherited Metabolic Disease · 2023

DOI: 10.1002/jimd.12619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2023. Verfasst von David E Sleat und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey, USA. Hauptthemen laut MEDLINE: Neuronal Ceroid-Lipofuscinoses, Tripeptidyl-Peptidase 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Batten Disease Support and Research Association, Beyond Batten Disease Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Late‐infantile neuronal ceroid lipofuscinosis (LINCL) and juvenile neuronal ceroid lipofuscinosis (JNCL) are inherited neurodegenerative diseases caused by mutations in the genes encoding lysosomal proteins tripeptidyl peptidase 1 (TPP1) and CLN3 protein, respectively. TPP1 is well‐understood and, aided by animal models that accurately recapitulate the human disease, enzyme replacement therapy has been approved and other promising therapies are emerging. In contrast, there are no effective treatments for JNCL, partly because the function of the CLN3 protein remains unknown but also because animal models have attenuated disease and lack robust survival phenotypes. Mouse models for LINCL and JNCL, with mutations in Tpp1 and Cln3 , respectively, have been thoroughly characterized but the phenotype of a double Cln3 / Tpp1 mutant remains unknown. We created this double mutant and find that its phenotype is essentially indistinguishable from the single Tpp1 −/− mutant in terms of survival and brain pathology. Analysis of brain proteomic changes in the single Tpp1 −/− and double Cln3 −/− ; Tpp1 −/− mutants indicates largely overlapping sets of altered proteins and reinforces earlier studies that highlight GPNMB, LYZ2, and SERPINA3 as promising biomarker candidates in LINCL while several lysosomal proteins including SMPD1 and NPC1 appear to be altered in the Cln3 −/− animals. An unexpected finding was that Tpp1 heterozygosity significantly decreased lifespan of the Cln3 −/− mouse. The truncated survival of this mouse model makes it potentially useful in developing therapies for JNCL using survival as an endpoint. In addition, this model may also provide insights into CLN3 protein function and its potential functional interactions with TPP1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuronal Ceroid-LipofuscinosesTripeptidyl-Peptidase 1AnimalsMiceBrainDisease Models, AnimalMembrane GlycoproteinsMolecular ChaperonesMutationProteomics

Stichwörter der Autor:innen

CLN3 proteinmouseneuronal ceroid lipofuscinosistripeptidyl peptidase 1

Substanzen

CLN3 protein, mouseGPNMB protein, humanMembrane GlycoproteinsMolecular ChaperonesTripeptidyl-Peptidase 1

Autor:innen und Institutionen

  • Center for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, New Jersey, USA.
  • Department of Biochemistry and Molecular Biology, Robert Wood Johnson Medical School, Rutgers Biomedical Health Sciences, Rutgers University, Piscataway, New Jersey, USA.
  • The Lundquist Institute (formerly Los Angeles Biomedical Research Institute), Harbor-UCLA Medical Center, and David Geffen School of Medicine, University of California, Torrance, California, USA.
  • Department of Pediatrics, Division of Genetics and Genomic Medicine, Washington University in St Louis, School of Medicine, St Louis, Missouri, USA.
  • Department of Genetics, Division of Genetics and Genomic Medicine, Washington University in St Louis, School of Medicine, St Louis, Missouri, USA.
  • Department of Neurology, Division of Genetics and Genomic Medicine, Washington University in St Louis, School of Medicine, St Louis, Missouri, USA.

ORCID-Profile: David E Sleat

Förderung

  • NINDS NIH HHS
  • Batten Disease Support and Research Association
  • Beyond Batten Disease Foundation
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Sleat, D. E., Banach-Petrosky, W., Larrimore, K. E., Nemtsova, Y., Wiseman, J. A., Najafi, A., Johnson, D., Poole, T. A., Takahashi, K., Cooper, J. D., & Lobel, P. (2023). A mouse mutant deficient in both neuronal ceroid lipofuscinosis‐associated proteins CLN3 and TPP1. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12619

Vancouver

Sleat DE, Banach-Petrosky W, Larrimore KE, Nemtsova Y, Wiseman JA, Najafi A, et al. A mouse mutant deficient in both neuronal ceroid lipofuscinosis‐associated proteins CLN3 and TPP1. Journal of Inherited Metabolic Disease. 2023. doi:10.1002/jimd.12619

BibTeX
@article{Sleat2023,
  author = {Sleat, David E and Banach-Petrosky, Whitney and Larrimore, Katherine E and Nemtsova, Yuliya and Wiseman, Jennifer A and Najafi, Allison and Johnson, Dymonn and Poole, Timothy A and Takahashi, Keigo and Cooper, Jonathan D and Lobel, Peter},
  title = {A mouse mutant deficient in both neuronal ceroid lipofuscinosis‐associated proteins CLN3 and TPP1},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2023},
  doi = {10.1002/jimd.12619}
}
Kostenlos starten →